Osmol gap as a surrogate marker for serum propylene glycol concentrations in patients receiving lorazepam for sedation

Pharmacotherapy

Volumn 26, Issue 1, 2006, Pages 23-33

  Barnes, Brian J ^a,c   Gerst, Christopher ^b   Smith, Jennifer R ^a   Terrell, Andrea R ^b   Mullins, Michael E ^b  

^a BARNES JEWISH HOSPITAL   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

Author keywords

Hyperosmolality; Lactate; Lorazepam; Osmol gap; Propylene glycol; Toxicology

Indexed keywords

AMPRENAVIR; CHLORDIAZEPOXIDE; COTRIMOXAZOLE; DIAZEPAM; DIGOXIN; DIMENHYDRINATE; ESMOLOL; ETOMIDATE; GLYCERYL TRINITRATE; HYDRALAZINE; LACTIC ACID; LORAZEPAM; LOXAPINE; MULTIVITAMIN; PENTOBARBITAL; PHENOBARBITAL; PHENYTOIN; PHYTOMENADIONE; PROPYLENE GLYCOL; SEDATIVE AGENT; SULFADIAZINE SILVER;

ADULT; AGED; ARTICLE; ARTIFICIAL VENTILATION; BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE MARKER; DRUG INFUSION; DRUG MEGADOSE; FEMALE; HOSPITAL ADMISSION; HUMAN; HYPEROSMOLALITY; INTENSIVE CARE UNIT; LACTATE BLOOD LEVEL; MALE; OSMOLARITY; PROSPECTIVE STUDY; SEDATION;

ADOLESCENT; ADULT; AGED; FEMALE; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; HUMANS; HYPNOTICS AND SEDATIVES; INFUSIONS, INTRAVENOUS; INTENSIVE CARE; LACTIC ACID; LINEAR MODELS; LORAZEPAM; MALE; MIDDLE AGED; OSMOLAR CONCENTRATION; PHARMACEUTICAL SOLUTIONS; PROPYLENE GLYCOL; RESPIRATION, ARTIFICIAL; SOLVENTS;

EID: 30544455514     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.2006.26.1.23     Document Type: Article

References (51)

1. Anonymous. 1976 Code of federal regulations. Title 21, volume 6, part 582, subpart B, section 582.1666. April 1, 2003. Rockville, MD: Food and Drug Administration.
2. World Health Organization. Toxicological evaluation of certain food additives with a review of general principles and specifications, 17th report. Geneva, Switzerland: World Health Organization, 1974.
3. Lemeshow S, Teres D, Pastides H, Avrunin JS, Steingrub JS. A method for predicting survival and mortality of ICU patients using objectively derived weights. Crit Care Med 1985;13(7):519-25.
4. Lemeshow S, Teres D, Klar J, Avrunin JS, Gehlbach SH, Rapoport J. Mortality probability models (MPM II) based on an international cohort of intensive care unit patients. JAMA 1993;270(20):2478-86.
5. Lemeshow S, Klar J, Teres D, et al. Mortality probability models for patients in the intensive care unit for 48 or 72 hours: a prospective, multicenter study. Crit Care Med 1994;22(9):1351-8.
6. Castella X, Artigas A, Bipn J, Kari A. A comparison of severity of illness scoring systems for intensive care unit patients: results of a multicenter, multinational study: the European/North American severity study group. Crit Care Med 1995;23(8):1327-35.
7. Rue M, Artigas A, Alvarez M, Quintana S, Valero C. Performance of the mortality probability models in assessing severity of illness during the first week in the intensive care unit. Crit Care Med 2000;28(8):2819-24.
8. Dorwart WV, Chalmers L. Comparison of methods for calculating serum osmolality from chemical concentrations, and the prognostic value of such calculations. Clin Chem 1975;21(2):190-4.
9. Erstad BL. Osmolality and osmolarity: narrowing the terminology gap. Pharmacotherapy 2003;23(9):1085-6.
10. Glasser L, Sternglanz PD, Combie J, Robinson A. Serum osmolality and its applicability to drug overdose. Am J Clin Pathol 1973;60(5):695-9.
11. Al Khafaji AH, Dewhirst WE, Manning HL. Propylene glycol toxicity associated with lorazepam infusion in a patient receiving continuous veno-venous hemofiltration with dialysis. Anesth Analg 2002;94(6):1583-5.
12. Arbour R, Esparis B. Osmolar gap metabolic acidosis in a 60-year-old man treated for hypoxemic respiratory failure. Chest 2000;118(2):545-6.
13. Arbour RB. Propylene glycol toxicity related to high-dose lorazepam infusion: case report and discussion. Am J Crit Care 1999;8(1):499-506.
14. Cawley MJ. Short-term lorazepam infusion and concern for propylene glycol toxicity: case report and review. Pharmacotherapy 2001;21(9):1140-4.
15. Chicella M, Jansen P, Parthiban A, et al. Propylene glycol accumulation associated with continuous infusion of lorazepam in pediatric intensive care patients. Crit Care Med 2002;30(12):2752-6.
16. D'Ambrosio J, Borchart-Phelps P, Nolen J, Cerra F. Propylene glycol-induced lactic acidosis secondary to a continuous infusion of lorazepam [abstr]. Pharmacotherapy 1993;13(3):274.
17. Hayman M, Seidl E, Anderson J, Harchelroad F. Monitoring lorazepam induced propylene glycol toxicity in a critical care population: a prospective case series [abstr]. Crit Care Med 2001;30(12):A157.
18. Hayman M, Seidl E, Ali M, Malik K. Acute tubular necrosis associated with propylene glycol from concomitant administration of intravenous lorazepam and trimethoprimsulfamethoxazole. Pharmacotherapy 2003;23(9):1190-4.
19. Kallas P. Significant osmolar gap and anion gap metabolic acidosis from high-dose lorazepam infusion in a critically ill adolescent. J Toxicol 2000;38:538-9.
20. Laine GA, Hossain SM, Solls RT, Adams SC. Polyethylene glycol nephrotoxicity secondary to prolonged high-dose intravenous lorazepam. Ann Pharmacother 1995;29(11):1110-14.
21. Parker MG, Fraser GL, Watson DM, Riker RR. Removal of propylene glycol and correction of increased osmolar gap by hemodialysis in a patient on high dose lorazepam infusion therapy. Intensive Care Med 2002;28(1):81-4.
22. Reynolds HN, Teiken P, Regan ME, et al. Hyperlactatemia, increased osmolar gap, and renal dysfunction during continuous lorazepam infusion. Crit Care Med 2000;28(5):1631-4.
23. Seay RE, Graves PJ, Wilkin MK. Comment: possible toxicity from propylene glycol in lorazepam infusion. Ann Pharmacother 1997;31(5):647-8.
24. Tayar J, Jabbour G, Saggi SJ. Severe hyperosmolar metabolic acidosis due to a large dose of intravenous lorazepam. N Engl J Med 2002;346(16):1253-4.
25. Tuohy KA, Nicholson WJ, Schiffman F. Agitation by sedation. Lancet 2003;361(9354):308.
26. Taucher N, Fish J, Smith H, Wells J. Propylene glycol-associated renal toxicity from lorazepam infusion. Pharmacotherapy 2003;23(9):1094-9.
27. Arroliga AC, Shehab N, McCarthy K, Gonzales JP. Relationship of continuous infusion lorazepam to serum propylene glycol concentration in critically ill adults. Crit Care Med 2004;32:1709-14.
28. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16(1):31-41.
29. Yu DK, Elmquist WF, Sawchuk RJ. Pharmacokinetics of propylene glycol in humans during multiple dosing regimens. J Pharm Sci 1985;74(8):876-9.
30. Speth PA, Vree TB, Neilen NF, et al. Propylene glycol pharmacokinetics and effects after intravenous infusion in humans. Ther Drug Monit 1987;9(3):255-8.
31. Ruddick JA. Toxicology, metabolism, and biochemistry of 1,2-propanediol. Toxicol Appl Pharmacol 1972;21(1):102-11.
32. Bekeris L, Baker C, Fenton J, Kimball D, Bermes E. Propylene glycol as a cause of an elevated serum osmolality. Am J Clin Pathol 1979;72(4):633-6.
33. Kulick MI, Lewis NS, Bansal V, Warpeha R. Hyperosmolality in the burn patient: analysis of an osmolal discrepancy. J Trauma 1980;20(3):223-8.
34. Fligner CL, Jack R, Twiggs GA, Raisys VA. Hyperosmolality induced by propylene glycol: a complication of silver sulfadiazine therapy. JAMA 1985;253(11):1606-9.
35. Peleg O, Bar-Oz B, Arad I. Coma in a premature infant associated with the transdermal absorption of propylene glycol. Acta Paediatr 1998;87(11):1195-6.
36. Yorgin PD, Theodorou AA, Al Uzri A, Davenport K, Boyer-Hassen LV, Johnson MI. Propylene glycol-induced proximal renal tubular cell injury. Am J Kidney Dis 1997;30(1):134-9.
37. Levy ML, Aranda M, Zelman V, Giannotta SL. Propylene glycol toxicity following continuous etomidate infusion for the control of refractory cerebral edema. Neurosurgery 1995;37(2):363-9.
38. Van de WB, Rubinstein E, Peacock W, Martin N. Propylene glycol toxicity caused by prolonged infusion of etomidate. J Neurosurg Anesthesiol 1995;7(4):259-62.
39. Glasgow AM, Boeckx RL, Miller MK, MacDonald MG, August GP, Goodman Sl. Hyperosmolality in small infants due to propylene glycol. Pediatrics 1983;72(3):353-5.
40. Demey HE, Daelemans RA, Verpooten GA, et al. Propylene glycol-induced side effects during intravenous nitroglycerin therapy. Intensive Care Med 1988;14(3):221-6.
41. Wheless JW. Pediatric use of intravenous and intramuscular phenytoin: lessons learned. J Child Neurol 1998;13(suppl 1):S11-14.
42. Glover ML, Reed MD. Propylene glycol: the safe diluent that continues to cause harm. Pharmacotherapy 1996;16(4):690-3.
43. Funk JO, Maibach HI. Propylene glycol dermatitis: reevaluation of an old problem. Contact Dermatitis 1994;31(4):236-41.
44. Fisher AA. Systemic contact dermatitis due to intravenous Valium in a person sensitive to propylene glycol. Cutis 1995;55(6):327-8.
45. Catanzaro JM, Smith JG Jr. Propylene glycol dermatitis. J Am Acad Dermatol 1991;24(1):90-5.
46. Arulanantham K, Genel M. Central nervous system toxicity associated with ingestion of propylene glycol. J Pediatr 1978;93(3):515-16.
47. Lolin Y, Francis DA, Flanagan RJ, Little P, Lascelles PT. Cerebral depression due to propylene glycol in a patient with chronic epilepsy: the value of the plasma osmolal gap in diagnosis. Postgrad Med J 1988;64(754):610-13.
48. Col J, Col-Debeys C, Lavenne-Pardonge E, et al. Propylene glycol-induced heparin resistance during nitroglycerin infusion. Am Heart J 1985;110(1 pt 1):171-3.
49. Habbab MA, Haft JI. Heparin resistance induced by intravenous nitroglycerin: a word of caution when both drugs are used concomitantly. Arch Intern Med 1987;147(5):857-60.
50. Wilson KC, Reardon C, Farber HW. Propylene glycol toxicity in a patient receiving intravenous diazepam [letter]. N Engl J Med 2000;343(11):815.
51. Bedichek E, Kirschbaum B. A case of propylene glycol toxic reaction associated with etomidate infusion. Arch Intern Med 1991;151(11):2297-8.